Antibiotic Treatment for Inpatient Community-Acquired Pneumonia
For non-ICU inpatients with community-acquired pneumonia, use either a respiratory fluoroquinolone (levofloxacin 750 mg IV daily) OR a β-lactam (ceftriaxone, cefotaxime, or ampicillin) plus a macrolide (azithromycin). 1
Treatment Algorithm Based on Severity
Non-ICU Inpatients (Moderate CAP)
The 2007 IDSA/ATS guidelines provide two equally strong evidence-based options 1:
- Option 1: Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg IV daily or moxifloxacin)
- Option 2: β-lactam (ceftriaxone, cefotaxime, or ampicillin) PLUS macrolide (azithromycin preferred)
Important nuance: Recent evidence suggests β-lactam monotherapy may be sufficient for moderate CAP 2, as macrolides carry risks of cardiac adverse events and resistance development. However, the established guidelines still recommend combination therapy, and this remains standard practice until newer guidelines formally change recommendations.
ICU Patients (Severe CAP)
Combination therapy is mandatory for severe CAP 1, 3:
- β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either:
- Azithromycin (Level II evidence), OR
- Respiratory fluoroquinolone (Level I evidence)
The β-lactam plus macrolide combination has the strongest evidence for reducing mortality in severe CAP 3, with a network meta-analysis showing it significantly outperforms β-lactam monotherapy (RR 0.79) and β-lactam plus fluoroquinolone combinations (RR 0.67).
Special Pathogen Coverage
When to Add MRSA Coverage
Add vancomycin (15 mg/kg IV q8-12h, target trough 15-20 mg/mL) OR linezolid (600 mg IV q12h) if 1:
- Prior IV antibiotics within 90 days
- Known MRSA colonization
- Severe necrotizing pneumonia
- Post-influenza pneumonia
When to Add Pseudomonas Coverage
Use antipseudomonal β-lactam (piperacillin-tazobactam 4.5g q6h, cefepime 2g q8h, or meropenem 1g q8h) PLUS either ciprofloxacin or levofloxacin 750mg if 1:
- Structural lung disease (bronchiectasis, cystic fibrosis)
- Recent hospitalization with broad-spectrum antibiotics
- Severe immunosuppression
Critical pitfall: The 2019 guidelines strongly recommend ABANDONING the "healthcare-associated pneumonia" (HCAP) category 4. Do not automatically use broad-spectrum antibiotics just because a patient lives in a nursing home or was recently hospitalized—only add MRSA/Pseudomonas coverage if locally validated risk factors exist.
Duration of Therapy
For non-severe CAP with clinical stability by day 3: treat for minimum 3 days 5, 6. Clinical stability means:
- Temperature ≤37.8°C
- Heart rate ≤100 bpm
- Respiratory rate ≤24/min
- Systolic BP ≥90 mmHg
- Oxygen saturation ≥90% on room air
- Able to take oral medications
For severe CAP: minimum 5 days of antibiotics 5
This represents a major shift from older 7-10 day recommendations and reduces antibiotic exposure without compromising outcomes 6.
Corticosteroids
Consider corticosteroids ONLY for severe CAP requiring ICU admission 5, 7. Recent evidence from REMAP-CAP has made this less clear, and corticosteroids should NOT be used routinely in non-severe pneumonia 5. Never use corticosteroids in influenza-associated pneumonia 8.
Key Clinical Pitfalls
Don't withhold antibiotics based solely on positive viral testing 5, 7—patients with imaging findings consistent with pneumonia or any comorbidities should receive antibiotics even with positive respiratory viral panels
Switch to oral therapy early—as soon as patients are clinically stable and can tolerate oral intake, typically within 48-72 hours 1
De-escalate based on cultures—if MRSA/Pseudomonas coverage was started empirically but cultures are negative, stop these agents promptly 4
Fluoroquinolone monotherapy is NOT recommended for severe CAP 4—combination therapy is essential for ICU patients